10128878ProVision-RA FS: Feasibility study for a combined, early warning precision medicine biomarker system to support proactive, personalised treatments for rheumatoid arthritis patientsClosedCollaborative R&DInnovate UKThis is a TRL3-stage feasibility study for **ProVision-RA**, a long-range prognostic and predictive combination biomarker system to support a precision medicine (PM) approach to healthcare for rheumatoid arthritis (RA) patients. ProVision-RA is being developed by the **ProVision Consortium** (**PC**), which is comprised of six health tech SMEs and two medical research centres. The project is to answer key questions about ProVision-RA's translation and deployment in Northern Ireland (NI), the mainland UK, and Ireland. RA is one of several high-burden chronic inflammatory diseases (cIDs) impacting these territories. ProVision-RA addresses two critical issues in current RA medicine: 1. _Late Action:_ RA diagnosis and treatment occur after the disease has fully developed. 2. _Imprecision:_ Clinicians use guesswork in selecting drugs for non-responding patients. Both problems stem from the current lack of effective chronic inflammation (cI) biomarkers - an issue affecting healthcare for virtually every other cID. ProVision-RA would address this by combining three types of information: 1. Omics biomarkers (including glycomics patterns of immune system components), 2. Conventional clinical markers, and 3. Digitally-acquired patient data. These data are used to: 1. Render disease-specific cI processes visible at early stages of disease progression and flare development and 2. Model the patient's likely future health trajectory. This multi-biomarker concept is being tested in ProVision-IBD, a similar biomarker system for inflammatory bowel disease (IBD) now at TRL6\. PC's TRL5 clinical studies on ProVision-IBD show it provides reliable long-range prognoses for IBD patients, allowing clinicians to take early action to mitigate inflammation. We also have preliminary data showing that the glycomic signals of ProVision-IBD can indicate patients' likely response to specific biologic drugs, enhancing clinicians' ability to choose effective therapeutics for non-responsive patients. Preliminary work shows that ProVision-RA could use ProVision-IBD's framework and provide similar advantages. This study will help validate our assumptions. Four Consortium members will do the work, with Mendez-Weiss leading and Avenna, Ludger, and Precision Medicine Centre, Univ Ulster (PMCU) as subcontractors. **Workpackages** are: 1. WP1-Project: Project management. \[£2,300\] 2. WP2-Needs: Assess needs for improved RA medicine in NI. \[£7,700\] 3. WP3-Economics: Develop robust healthcare economics model for ProVision-RA. \[£7,100\] 4. WP4-Applications: Assess potential clinical utility of ProVision-RA and routes for its integration into current clinical pathways. \[£11,300\] 5. WP5-Glycomics: Assess the value of blood glycomics data in ProVision-RA. \[£4,100\] 6. WP6-Algorithms: Assess algorithms for integrating and analysing data for diverse RA biomarkers in ProVision-RA. \[£13,422\] 7. WP7-Roadmap: Produce a high-level roadmap for translation (to TRL9) of ProVision-RA. \[£4,050\] The total budget for the 6-month project is **£49,972\.**